Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 06:51 am Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:08 pm Purchase | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% | 4,040,285 (+4.09%) | Filing History |
| 2022-02-10 4:26 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% | 98,809,158 (New Position) | Filing History |
| 2021-06-15 09:19 am Sale | 2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% | -2,521,914 (-55.35%) | Filing History |
| 2021-02-16 12:06 pm Purchase | 2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% | 1,267,940 (+38.56%) | Filing History |
| 2020-03-25 4:16 pm Purchase | 2020-03-18 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 3,288,091 9.990% | 3,288,091 (New Position) | Filing History |
| 2020-02-25 08:32 am Sale | 2020-02-21 | 13G | Intec Pharma Ltd NTEC | Dexcel Pharma Technologies Ltd. | 26,465 4.070% | -26,471 (-50.01%) | Filing History |